课题基金 / 基金详情

项目摘要

项目成果

Jian-Ting Zhang的其他基金

相关文献

中文摘要
翻译
多药耐药(MDR)是人类肿瘤化疗成功的主要问题。一 已知的癌细胞多药耐药机制之一是膜蛋白表达增加, 调节抗癌药物的外流。具有这种药物外排功能的三种主要膜蛋白 已发现:P-糖蛋白(Pgp)、多药耐药相关蛋白(MRP1)和乳房 肿瘤耐药蛋白/米托蒽醌耐药蛋白(BCRP/MXR)。这些蛋白质属于ATP- 结合盒(ABC)膜转运蛋白超家族,又称ABCB1、ABCC1和 ABCG2。我们实验室的长期目标是了解其分子机制。 克服ABC转运蛋白介导的癌细胞多药耐药。 ‘与人ABCB1和ABCC1不同,人ABCG2的核苷酸是半ABC转运体 结合结构域位于氨基末端,被认为具有同源二聚体的功能。然而, 我们最近的研究表明,它是以同源异构体的形式存在的。在此应用程序中,我们计划测试 假设人类ABCG2作为同源二聚体而不是主要的同源二聚体起作用 可以靶向齐聚过程来逆转ABCG2介导的耐药性。为此,我们计划 完成以下五个具体目标:(1)确定人ABCG2是同源二聚体还是 同源十聚体;(2)确定人ABCG2的十二聚体形式是否为功能转运体;(3) 确定人ABCG2的寡聚化是否发生在内质网(ER);(4)确定 人ABCG2的羧基跨膜结构域是否与齐聚有关;(5)确定 是否有可能通过破坏ABCG2的寡聚过程来逆转其介导的耐药性。 印第安纳大学癌症研究所优越的科学环境和慷慨的 机构支持将极大地促进这一项目的成功。该信息和 本研究获得的探针有助于我们了解ABCG2介导的人ABCG2的分子机制 毒品运输。这项工作还可能使我们发现一种新的治疗剂,它可以帮助 战胜抗药性癌症。
英文摘要
Multidrug resistance (MDR) is a major problem for successful chemotherapy of human cancers. One of the known mechanisms of MDR in cancer cells is the elevated expression of membrane proteins that mediate the efflux of anticancer drugs. Three major membrane proteins that have this drug-efflux function have been identified: P-glycoprotein (Pgp), multidrug resistance-associated proteinl (MRP1), and breast cancer resistance protein/mitoxantrone resistance protein (BCRP/MXR). These proteins belong to the ATP- binding cassette (ABC) membrane transporter superfamily and are also named as ABCB1, ABCC1, and ABCG2, respectively. The long-term goal of our laboratory is to understand the molecular mechanisms of and to overcome ABC transporter-mediated MDR in cancer cells. ' Unlike human ABCB1 and ABCC1, human ABCG2 is a half ABC transporter with its nucleotide binding domain located at the amino terminus and has been thought to function as a homodimer. However, our recent studies suggest that it exists as a homododecamer. In this application, we plan to test the hypothesis that human ABCG2 functions as a homododecamer rather than the prevailing homodimer and we can target the oligomerization process to reverse ABCG2-mediated drug resistance. To this end, we plan to accomplish the following five specific aims: (1) to determine if human ABCG2 is a homodimer or homododecamer; (2) to determine if the dodecameric form of human ABCG2 is a functional transporter; (3) to determine if the oligomerization of human ABCG2 occurs in the endoplasmic reticulum (ER); (4) to determine if the carboxyl transmembrane domain of human ABCG2 is responsible for oligomerization; (5) to determine if it is possible to reverse ABCG2-mediated drug resistance by disrupting its oligomerization process. The excellent scientific environment at Indiana University Cancer Research Institute and the generous institutional support will contribute enormously to the likelihood of success of this project. The information and probes obtained from this study will help us understand the molecular mechanism of human ABCG2-mediated drug transport. This work may also lead us to the discovery of a new class of therapeutic agents that can help overcome drug-resistant cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting FASN to eliminate metastatic breast cancer in the brain
Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway
Molecular targeting the translational control axis in Wnt/beta-catenin signaling pathway
Molecular targeting the translational control axis in Wnt/β-catenin signaling pathway